Status:
COMPLETED
Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer
Lead Sponsor:
Eli Lilly and Company
Conditions:
Pancreatic Neoplasm
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to determine the effects and toxicity of gemcitabine alone or gemcitabine plus enzastaurin in participants with pancreatic cancer.
Eligibility Criteria
Inclusion
- Diagnosis of adenocarcinoma of the pancreas.
- Pretreatment tumor specimen must be available.
- No prior chemotherapy immunotherapy, biological therapy, or hormonal therapy for pancreatic cancer, including 5-fluorouracil (5-FU) with radiation therapy.
- Prior radiation allowed.
- Ability to stop some types of anti-seizure medicines within 14 days of enrollment.
Exclusion
- Endocrine pancreatic tumor or ampullary cancer.
- Central Nervous System (CNS) metastases.
- Inability to swallow tablets.
- 10% or greater weight loss over the 6 weeks before study entry.
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00267020
Start Date
December 1 2005
End Date
May 1 2008
Last Update
August 31 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician
Dallas, Texas, United States